Events

Join Drug Delivery Leader's Chief Editor Tom von Gunden as he engages drug delivery experts Beate Bittner, Shannon Hoste, Jonathan Amaya-Hodges, and Fran DeGrazio in a discussion of innovations and advances in injectable, infusible, and implantable devices, systems, platforms, and combinations. Focusing on unmet patient needs and expanded therapeutic targets, the panel will discuss approaches...

Join KBI Biopharma and Argonaut Manufacturing Services for a candid fireside chat on breaking down silos between drug substance and drug product. Explore how an integrated, quality-aligned approach can simplify execution and reduce timelines by 2–3 months from cell line development to drug product manufacturing. What you’ll learn: * How to overcome common CDMO and...

Watch industry experts share practical guidance on how to evaluate CDMOs beyond the basics—focusing on experience, talent, and technologies that align with your development goals. Speakers: Jana Spes, CEO & Co-founder, JT Biopharma Partners Peter Bigelow, CEO & Co-founder, SCmple Solutions Christine Sheaffer, Manufacturing & Supply Consultant, Executive Leader Biotech Industry Jeff Buguliskis, PhD, Chief...

Join West Pharmaceutical Services for a discussion on how to simplify the complex process of selecting a prefillable syringe system. With combination product requirements and ambiguous regulations, traditional evaluation and testing can slow development and delay clinical timelines. This presentation introduces the West Synchrony™ S1 Prefillable Syringe System—a fully integrated, verified solution combining the barrel,...

The road to first-in-human is one of the most pivotal—and complex—stages in drug development. It’s a journey that requires foresight, coordination, and a clear map connecting scientific innovation to operational execution. In this live webinar, experts from inSeption Group will outline proven strategies for navigating each phase of early clinical readiness and IND preparation. Learn...

The rapid growth of complex antibody modalities—including bispecifics, multispecifics, Fc-fusions, and emerging formats—has widened the gap between discovery-stage expression systems and manufacturability. Transient expression, still widely used for screening and optimization, often fails to reveal architecture-driven liabilities such as chain imbalance, mispairing, instability, aggregation, or poor effective yield. As a result, promising molecular formats may...

Join Bioprocess Online Chief Editor Tyler Menichiello on February 11, at 11 a.m. Eastern, for an interactive panel discussion exploring how upstream and downstream development teams can work together to reduce risk, accelerate process scaling, and support smoother downstream tech transfer. The panel will feature Eric Doerr, drug substance technical lead at Sanofi; Mark Fitchmun,...

Watch leading CDMOs share their current capabilities, facility locations, and timelines—helping you identify the right partners for your small molecule drug product development and manufacturing needs. What to expect: - Short digital presentations providing an inside look at supplier capacity - Live Q&A to ask questions and assess whether each CDMO can meet your needs...

Watch leading CDMOs share their current capabilities, facility locations, and timelines—helping you identify the right partners for your cell and gene development and manufacturing needs. Explore the fast-growing field of cell and gene therapy, including: - Cell sourcing and expansion - Vector design and gene therapy delivery mechanisms - Formulation development and GMP-compliant processes ensuring...